HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Early and Sustained Increases in Leukotriene B4 Levels Are Associated with Poor Clinical Outcome in Ischemic Stroke Patients.

Abstract
Leukotriene B4 (LTB4) has been implicated in ischemic stroke pathology. We examined the prognostic significance of LTB4 levels in patients with acute middle cerebral artery (MCA) infarction and their mechanisms in rat stroke models. In ischemic stroke patients with middle cerebral artery infarction, plasma LTB4 levels were found to increase rapidly, roughly doubling within 24 h when compared to initial post-stroke levels. Further analyses indicate that poor functional recovery is associated with early and more sustained increase in LTB4 rather than the peak levels. Results from studies using a rat embolic stroke model showed increased 5-lipoxygenase (5-LOX) expression in the ipsilateral infarcted cortex compared with sham control or respective contralateral regions at 24 h post-stroke with a concomitant increase in LTB4 levels. In addition, neutrophil influx was also observed in the infarcted cortex. Double immunostaining indicated that neutrophils express 5-LOX and leukotriene A4 hydrolase (LTA4H), highlighting the pivotal contributions of neutrophils as a source of LTB4. Importantly, rise in plasma LTB4 levels corresponded with an increase in LTB4 amount in the infarcted cortex, thereby supporting the use of plasma as a surrogate for brain LTB4 levels. Pre-stroke LTB4 loading increased brain infarct volume in tMCAO rats. Conversely, administration of the 5-LOX-activating protein (FLAP) inhibitor BAY-X1005 or B-leukotriene receptor (BLTR) antagonist LY255283 decreased the infarct volume by a similar extent. To conclude, targeted interruption of the LTB4 pathway might be a viable treatment strategy for acute ischemic stroke.
AuthorsSu Jing Chan, Mary P E Ng, Hui Zhao, Geelyn J L Ng, Chuan De Foo, Peter T-H Wong, Raymond C S Seet
JournalNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (Neurotherapeutics) Vol. 17 Issue 1 Pg. 282-293 (01 2020) ISSN: 1878-7479 [Electronic] United States
PMID31520306 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Leukotriene A4
  • Leukotriene B4
  • Arachidonate 5-Lipoxygenase
Topics
  • Aged
  • Animals
  • Arachidonate 5-Lipoxygenase (metabolism)
  • Cerebral Cortex (metabolism)
  • Disease Models, Animal
  • Female
  • Humans
  • Infarction, Middle Cerebral Artery (blood, complications, diagnosis)
  • Leukotriene A4 (metabolism)
  • Leukotriene B4 (blood)
  • Male
  • Middle Aged
  • Rats, Wistar
  • Severity of Illness Index
  • Stroke (blood, complications, diagnosis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: